BioAtla, Inc.

BioAtla, Inc. is a clinical stage biopharmaceutical company specializing in the development of specific antibody-based therapeutics for solid tumor cancer treatment. Their lead product candidate, BA3011, is a conditionally active biologic (CAB) antibody-drug conjugate (ADC) targeting soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, they are developing BA3021, a CAB ADC for multiple solid tumor types, and BA3071, a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for various cancers.

Products

• BA3011 - CAB ADC for soft tissue and bone sarcoma tumors, NSCLC, and ovarian cancer

• BA3021 - CAB ADC for multiple solid tumor types

• BA3071 - CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for various cancers